Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Employment among patients with kidney disease remains low even after dialysis or a transplant, with physical and social ...

For a disease afflicting 35.5 million people in the U.S., chronic kidney disease flies under the radar. Only half the people ...

Two significant programs that invested in research on diabetes, dementia, obesity and kidney disease have ended since the ...

In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.

(Courtesy/GettyImages) Millions of people around the world unknowingly live with a deadly trio: diabetes, high blood pressure and kidney disease. Often, they only realise the connection when it is ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Diabetes and high blood pressure are the two main culprits of chronic kidney disease (CKD), a long-term condition in which ...

The American College of Obstetrics and Gynecology now states that there is no need to discontinue safe blood pressure ...

A Diabetes, Heart Failure, and Kidney Disease Medication Is the First of Its Kind to Significantly Reduce Both Heart Attacks and Strokes Feb. 11, 2025 — Over 1,000 genes may serve as possible ...